Trial reportBMC pulmonary medicine2026
Improved quality of life, reduced quantitative lung fibrosis in a trial of inhaled pirfenidone for idiopathic pulmonary fibrosis.
Trial report in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAP01, a novel formulation of inhaled pirfenidone, has demonstrated potential for improved efficacy and safety for idiopathic pulmonary fibrosis (IPF) vs. oral pirfenidone. A 72-week phase 1b study, ATLAS, suggested reliable correlations between structural changes revealed by high-resolution computed tomography (HRCT) and functional changes in forced vital capacity (FVC). Correlations between symptom improvement and structural changes are less established. Using ATLAS data, this study aims to investigate correlations between quantitative HRCT scores and changes in patient-reported outcomes (PROs) in AP01-treated patients with IPF.
methodsPatients (N = 91) received AP01 50 mg qd or 100 mg bid. FVC, quantitative lung fibrosis (QLF), and PRO measures including King’s Brief Interstitial Lung Disease questionnaire (KBILD) assessed functional, structural, and symptomatic changes over 48 weeks. Non-contrast HRCTs were performed at baseline and 24 weeks; improvement was defined as > 2% decrease in QLF score.
resultsAmong 69 patients with sufficient quality HRCT scans, similar proportions on both regimens exhibited QLF improvement (50 mg qd: 16%; 100 mg bid:16%) and QLF stabilisation (-2% ≤ ∆QLF ≤ 2%) (50 mg qd: 47%; 100 mg bid: 55%). 100-mg bid subjects with improved QLF exhibited increased mean KBILD total scores from baseline beginning week 8 (8 points) through week 48 (> 20 points) (minimal clinically important difference = 5 points).
conclusionsA strong and lasting association between structural and symptomatic improvements confirms functional changes with AP01 and supports evaluation of the 100-mg bid dose. CLINICAL
trial registrationAustralianNew Zealand Clinical Trials Registry Identifier ACTRN 12,618,001,838,202 URL: https://www.anzctr.org.au the trial registration took place before the first patient enrolled trial registration was 12 November 2018 and first patient enrolled on 06 January 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.